Genus Capital Management Inc. Neurocrine Biosciences Inc Transaction History
Genus Capital Management Inc.
- $763 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
625Shares Held
94.2MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.78 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.26 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$647 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$323 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$234 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...